NNZ-2591 | Interleukin Related interleukin-related.com

Product Name :
NNZ-2591

Search keywords :
NNZ 2591

drugId :
null

Target Vo:
Neuropeptide receptor

Target Vo Short Name :
Neuropeptide receptor

Moa_Name:
Neuropeptide receptor modulators

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Neuren Pharmaceuticals Ltd

Active Company_Name :
Acadia Pharmaceuticals Inc

Active Indication_Name:
Wolf-Hirschhorn Syndrome

In Active Indication_Name:
Prader-Willi Syndrome

Termination Status :

China Termination Status :

Highest Status:
Phase 2 Clinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Bimekizumab Protocol
Efbemalenograstim alfa In Vivo
Bmi1 Antibody: Bmi1 Antibody is a non-conjugated and Mouse origined monoclonal antibody about 37 kDa, targeting to Bmi1. It can be used for WB,ICC,IHC-P,FC assays with tag free, in the background of Human, Mouse, Rat.

Author: Interleukin Related

Related Posts